Lineage Therap (BT3) Q2 2026 Earnings Report

The call presented meaningful technical and strategic progress: demonstrated scalable GMP manufacturing (AlloSCOPE), rapid internal pipeline expansion (COR1, ILT1, ReSonance), and partnership validation (Roche/Genentech, Demant). Financial reporting showed an apparent improvement to net income, extension of cash runway into Q3 2028, and an incremental $4.6M ATM raise. However, material weaknesses and near-term risks remain: Q2 revenue dropped substantially (~60.7% YoY), reported profitability was driven by noncash accounting items, cash runway still depends on contingent exercises/milestones, OpRegen advancement timing is dependent on partner-driven surgical optimization, and ILT1 faces major manufacturing scale challenges. Overall, positives around technology, partnerships and program breadth are tempered by funding, revenue dynamics and technical/partner-dependent execution risks.

Key guidance and metrics from the call: cash, cash equivalents and marketable securities were $50.8M as of June 30, 2026, expected to fund operations into Q3 2028; Lineage raised ≈$4.6M via an ATM on June 26 at a $1.28 weighted‑average price, is eligible for ≈$32M from warrant exercises (strike $0.91, 3‑year maturity; accelerates to 90 days on certain Roche/Genentech disclosures) and remains eligible for up to $615M in Roche/Genentech development/commercial milestones (management also cited the original collaboration included a $50M upfront + $620M in potential milestones), Q2 revenue was $1.1M (down $1.7M YoY from $2.8M), operating expenses were $10M (vs $22.5M YoY), R&D $4.8M, G&A $5.2M, loss from operations $8.9M (improved from $19.8M), other income of $10.5M from warrant remeasurement drove a net income of $1.5M (~$0.01 basic) versus a $30.5M loss a year earlier; operational milestones include OpRegen’s GAlette expansion from 6 to 17 sites and EMA IRIS registration, COR1 advancing to preclinical with in‑vivo data targeted by year‑end, AlloSCOPE 5D demonstrating a 0.5‑L suspension process and larger multi‑tier runs with a claimed ability to produce “millions” of vials, ReSonance’s Demant‑funded preclinical program (up to $12M) completing 3 engineering runs and a first GMP run now in release testing, and the DOSED study having dosed two chronic patients (one at 1 year, one at ~90 days) with no unexpected device/product‑related AEs and 1‑month DSMB pauses between the first four patients.